

Edgar Filing: RBS Holdings N.V. - Form FWP

RBS Holdings N.V.
Form FWP
February 03, 2012

Filed pursuant to Rule 433. Registration Statement Nos.
RBS Exchange Traded Notes 333-162219, 333-162219-01, 333-162193 and 333-162193-01 BUILDING

RBS ETN Performance -- as of 12/31/11

RBS Trendpilot[TM] ETNs

RBS Trendpilot[TM] ETNs track an RBS Trendpilot[TM] Index. RBS Trendpilot(TM) Indices alternate between tracking a Benchmark Index and a Cash Rate, depending on the performance of the Benchmark Index relative to its 100- or 200-Index business day simple moving average, as applicable.

RBS US Large Cap Trendpilot[TM] ETN (TRND) Historical Performance and Standard Deviation (%)

	1-MONTH (%)	3-MONTH (%)	1-YEAR (%)	YEAR-TO-DATE (%)	SINCE (%)
RBS US Large Cap Trendpilot[TM] ETN Daily Redemption Value(1)	-0.04	-0.12	-6.45	-6.45	
RBS US Large Cap Trendpilot(TM) Index (USD) (Index)	0.00	0.00	-5.69	-5.69	
SandP 500([R]) Total Return Index (Benchmark Index)	1.02	11.82	2.11	2.11	
SandP 500([R]) Index (Price Return)	0.85	11.15	0.00	0.00	
Cash rate on 12/31/11 was 0.025%	--	--	--	--	

RBS US Mid Cap Trendpilot[TM] ETN (TRNM) Historical Performance and Standard Deviation (%)

	1-MONTH (%)	3-MONTH (%)	1-YEAR (%)	YEAR-TO-DATE (%)	SINCE (%)
RBS US Mid Cap Trendpilot[TM] ETN Daily Redemption Value(1)	-0.04	-0.12	--	--	
RBS US Mid Cap Trendpilot(TM) Index (USD) (Index)	0.00	0.00	--	--	
SandP MidCap 400([R]) Total Return Index (Benchmark Index)	-0.37	12.98	--	--	
SandP MidCap 400([R]) Index (Price Return)	-0.52	12.53	--	--	
Cash rate on 12/31/11 was 0.025%	--	--	--	--	

RBS NASDAQ-100([R]) Trendpilot[TM] ETN (TNDQ) Historical Performance and Standard Deviation (%)

	1-MONTH (%)	3-MONTH (%)	1-YEAR (%)	YEAR-TO-DATE (%)	SINCE (%)
RBS NASDAQ-100([R]) Trendpilot[TM] ETN Daily Redemption Value(1)	--	--	--	--	
RBS NASDAQ-100([R]) Trendpilot(TM) Index (USD) (Index)	--	--	--	--	
NASDAQ-100([R]) Total Return Index(SM) (Benchmark Index)	--	--	--	--	
Cash rate on 12/31/11 was 0.025%	--	--	--	--	

RBS Gold Trendpilot[TM] ETN (TBAR) Historical Performance and Standard Deviation (%)

1-MONTH 3-MONTH 1-YEAR YEAR-TO- SINCE RBS ET

Edgar Filing: RBS Holdings N.V. - Form FWP

	(%)	(%)	(%)	DATE (%)	(2/17/2
RBS Gold Trendpilot [TM] ETN Daily Redemption Value(1)	-12.38	-5.73	--	--	10
RBS Gold Trendpilot (TM) Index (USD) (3) (Index)	-12.31	-5.49	--	--	11
Price of Gold Bullion (Benchmark Index)	-12.31	-5.49	--	--	11
Cash rate on 12/31/11 was 0.025%	--	--	--	--	

RBS Oil Trendpilot [TM] ETN (TWI) Historical Performance and Standard Deviation (%)

	1-MONTH (%)	3-MONTH (%)	1-YEAR (%)	YEAR-TO-DATE (%)	SINCE RBS (9/13
RBS Oil Trendpilot [TM] ETN Daily Redemption Value(1)	-0.89	4.03	--	--	4
RBS Oil Trendpilot (TM) Index (USD) (Index)	-0.81	4.23	--	--	4
RBS 12-Month Oil Total Return Index (Benchmark Index)	-0.81	23.25	--	--	8
Cash rate on 12/31/11 was 0.025%	--	--	--	--	

RBS Sector ETNs

RBS Sector ETNs track a sector-related Index.

RBS Global Big Pharma ETN (DRGS) Historical Performance and Standard Deviation (%)

	1-MONTH (%)	3-MONTH (%)	1-YEAR (%)	YEAR-TO-DATE (%)	SINCE RBS E (10/21
RBS Global Big Pharma ETN Daily Redemption Value(1)	3.90	--	--	--	6.
NYSE Arca Equal Weighted Pharmaceutical Total Return Index(SM) (Index)	3.95	--	--	--	6.

for registered broker/dealers and registered investment advisers only. not for distribution to individual investors.

Edgar Filing: RBS Holdings N.V. - Form FWP

The tables above present the actual performance of the respective indices and RBS ETNs over the specified periods. For information regarding the performance of each Index, please refer to the relevant pricing supplement filed with the U.S. Securities and Exchange Commission ("SEC"). Past performance does not guarantee future results.

(1) Includes the deduction of the annual investor fee, which accrues on a daily basis. The annual investor fee will be equal to: (i) (a) 1.00% per annum when the RBS US Large Cap Trendpilot(TM) Index (USD), RBS US Mid Cap Trendpilot(TM) Index (USD), RBS Gold Trendpilot(TM) Index (USD) and the RBS NASDAQ-100 ([R]) Trendpilot(TM) Index (USD) are tracking their respective Benchmark Indices and (b) 1.10% per annum when the RBS Oil Trendpilot(TM) Index (USD) is tracking its respective Benchmark Index; and (ii) 0.50% per annum when any of these Trendpilot(TM) Indices are tracking the Cash Rate. With respect to the RBS Global Big Pharma ETNs, the annual investor fee will be 0.60% per annum. (2) Based on daily returns. Standard deviation is a measure of volatility, and illustrates the extent of variation (whether higher or lower) that exists from the average given set of results. A low standard deviation indicates that the results tend to be very close to the average result (a low degree of volatility). In contrast, a high standard deviation indicates that the results are spread out over a large range of outcomes (a high degree of volatility). (3) Since the inception date of the RBS Gold Trendpilot(TM) ETNs, the RBS Gold Trendpilot(TM) Index (USD) has tracked the Price of Gold Bullion and has remained in a positive trend, without any trend reversal. Consequently, the historical performance of the RBS Gold Trendpilot(TM) Index (USD) over the time periods specified above is identical to the Price of Gold Bullion. In a negative trending market, the RBS Gold Trendpilot(TM) Index (USD) is expected to switch from positive to negative, and such Index is expected to experience trend reversals in volatile markets, switching from a positive to negative or from negative to positive, as the case may be.

CERTAIN RISK CONSIDERATIONS: The RBS ETNs involve risks not associated with an investment in conventional debt securities, including a possible loss of some or all of your investment. The level of the relevant Index must increase by an amount sufficient to offset the aggregate investor fee applicable to the RBS ETNs in order for you to receive at least the principal amount of your investment back at maturity or upon early repurchase or redemption. The Benchmark Index for the RBS Global Big Pharma ETNs comprises securities of a limited number of companies concentrated in the pharmaceuticals industry, and may not be representative of an investment that provides exposure to the pharmaceutical industry as a whole. The RBS Oil Trendpilot(TM) ETNs and the RBS Oil Trendpilot(TM) Index (USD) do not provide exposure to spot prices of crude oil and, consequently, may not be representative of an investment that provides exposure to crude oil. Each Trendpilot(TM) Index may underperform its respective Benchmark Index, and is expected to perform poorly in volatile markets. Liquidity of the market for RBS ETNs may vary over time. The RBS ETNs are not principal protected and do not pay interest. Any payment on the RBS ETNs is subject to the ability of the applicable issuer and guarantor to pay their respective obligations when they become due. You should carefully consider whether the RBS ETNs are suited to your particular circumstances before you decide to purchase them. We urge you to consult with your investment, legal, accounting, tax and other advisors with respect to any investment in the RBS ETNs.

The RBS ETNs are not suitable for all investors. You should carefully read the relevant pricing supplement and prospectus, including the more detailed explanation of the risks involved in any investment in the RBS ETNs as described in the "Risk Factors" section of the applicable pricing supplement, before investing.

Edgar Filing: RBS Holdings N.V. - Form FWP

IMPORTANT INFORMATION: The Royal Bank of Scotland plc (RBS plc), The Royal Bank of Scotland Group plc, The Royal Bank of Scotland N.V. (RBS N.V.) and RBS Holdings N.V. (collectively, the RBS Entities) have filed a registration statement (including a prospectus) with the Securities and Exchange Commission (SEC) for the offering of RBS ETNs to which this communication may relate. Before you invest in any RBS ETNs, you should read the relevant prospectus in such registration statement and other documents that have been filed with the SEC for more complete information about the relevant RBS Entities and offerings. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, RBS N.V., RBS plc, RBS Securities Inc. (RBSSI) or any dealer participating in the relevant offering will arrange to send you the relevant prospectus and pricing supplements if you request by calling 1-855-RBS-ETPS (toll-free).

RBS US Large Cap Trendpilot(TM) Index (USD), RBS US Mid Cap Trendpilot(TM) Index (USD) and RBS Gold Trendpilot(TM) Index (USD) are the property of The Royal Bank of Scotland plc, which has contracted with Standard and Poor's Financial Services LLC ("SandP") to maintain and calculate these Trendpilot(TM) Indices. The SandP 500([R]) Index and the SandP MidCap 400([R]) Index are the exclusive property of SandP and have been licensed for use by RBSSI and its affiliates in connection with the RBS US Large Cap Trendpilot(TM) Index (USD) and the RBS US Mid Cap Trendpilot(TM) Index (USD), respectively. SandP shall have no liability for any errors or omissions in calculating these Trendpilot(TM) Indices. "Standard and Poor's([R])", "SandP([R])", "SandP 500([R])" and "SandP MidCap 400([R])" are registered trademarks of SandP. "Calculated by SandP Custom Indices" and its related stylized mark are service marks of SandP and have been licensed for use by RBSSI and its affiliates. The RBS US Large Cap Trendpilot[TM] ETNs, RBS US Mid Cap Trendpilot[TM] ETNs and RBS Gold Trendpilot[TM] ETNs are not sponsored, endorsed, sold or promoted by SandP or its affiliates, and neither SandP nor its affiliates make any representation regarding the advisability of investing in such RBS ETNs.

NASDAQ([R]), OMX([R]), NASDAQ OMX([R]), NASDAQ-100([R]), NASDAQ-100 Index([R]) and NASDAQ-100([R]) Total Return Index(SM) are registered trademarks and service marks of The NASDAQ OMX Group, Inc. and are licensed for use by RBS plc. The RBS NASDAQ-100([R]) Trendpilot(TM) Index is the property of RBS plc. RBS plc has contracted with The NASDAQ OMX Group, Inc. (which with its affiliates and subsidiaries is referred to as the "Corporations") to calculate and maintain the RBS NASDAQ-100([R]) Trendpilot(TM) Index, either directly or through a third party. Currently, the RBS NASDAQ-100([R]) Trendpilot(TM) Index is calculated and maintained by Standard and Poor's ("SandP") on behalf of The NASDAQ OMX Group, Inc. SandP and the Corporations shall have no liability for any errors or omissions in calculating the Index. The RBS NASDAQ-100([R]) Trendpilot(TM) ETNs, which are based on the RBS NASDAQ-100([R]) Trendpilot(TM) Index, have not been passed on by the Corporations or SandP as to their legality or suitability and are not sponsored, endorsed, sold or promoted by the Corporations or SandP. THE CORPORATIONS AND SandP MAKE NO WARRANTIES AND BEAR NO LIABILITY WITH RESPECT TO THE RBS NASDAQ-100([R]) TRENDPILOT(TM) ETNs.

RBS Oil Trendpilot(TM) Index (USD) and RBS 12-Month Oil Total Return Index (USD) are the property of RBS plc and are calculated by NYSE Arca, a wholly-owned subsidiary of NYSE Euronext. The RBS Oil Trendpilot[TM] ETNs, which track the RBS Oil Trendpilot(TM) Index (USD) and RBS 12-Month Oil Total Return Index (USD), are not issued, sponsored, endorsed, sold or promoted by NYSE Arca, and NYSE Arca makes no representation regarding the advisability of investing in such ETNs. NYSE ARCA MAKES NO EXPRESS OR IMPLIED WARRANTIES, AND HEREBY EXPRESSLY DISCLAIMS ALL WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO THE RBS OIL TRENDPILOT[TM] INDEX (USD) OR RBS 12-MONTH OIL TOTAL RETURN INDEX (USD) OR ANY DATA INCLUDED THEREIN. IN NO EVENT SHALL NYSE ARCA HAVE ANY LIABILITY FOR ANY SPECIAL, PUNITIVE, INDIRECT, OR CONSEQUENTIAL DAMAGES (INCLUDING LOST PROFITS), EVEN IF NOTIFIED OF THE

Edgar Filing: RBS Holdings N.V. - Form FWP

POSSIBILITY OF SUCH DAMAGES.

The NYSE Arca Equal Weighted Pharmaceutical Index(SM) and the NYSE Arca Equal Weighted Pharmaceutical Total Return Index(SM) are service marks of NYSE Euronext or its affiliates (NYSE Euronext) and have been licensed for use by RBS plc and RBSSI (Licensees) in connection with the RBS Global Big Pharma ETNS. Neither the Licensees nor the RBS Global Big Pharma ETNS is sponsored, endorsed, sold or promoted by NYSE Euronext. NYSE Euronext makes no representations or warranties regarding the RBS Global Big Pharma ETNS or the ability of the NYSE Arca Equal Weighted Pharmaceutical Index(SM) or the NYSE Arca Equal Weighted Pharmaceutical Total Return Index(SM) to track general stock market performance. NYSE EURONEXT MAKES NO EXPRESS OR IMPLIED WARRANTIES, AND HEREBY EXPRESSLY DISCLAIMS ALL WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO THE NYSE ARCA EQUAL WEIGHTED PHARMACEUTICAL INDEXSM OR THE NYSE ARCA EQUAL WEIGHTED PHARMACEUTICAL TOTAL RETURN INDEXSM OR ANY DATA INCLUDED THEREIN. IN NO EVENT SHALL NYSE EURONEXT HAVE ANY LIABILITY FOR ANY SPECIAL, PUNITIVE, INDIRECT, OR CONSEQUENTIAL DAMAGES (INCLUDING LOST PROFITS), EVEN IF NOTIFIED OF THE POSSIBILITY OF SUCH DAMAGES.

Copyright[C] 2012 RBS Securities Inc. All rights reserved. RBS Securities Inc., a U.S. registered broker-dealer, member of FINRA and SIPC, is an indirect wholly-owned subsidiary of The Royal Bank of Scotland plc and an affiliate of RBS NV.

To find out more

Call toll free 855-RBS-ETPS or visit www.rbs.com/etnUS